

## 糖尿病・内分泌グループ

[欧文論文]

1. Nakamura A, Miyoshi H, Ukawa S, Nakamura K, Nakagawa T, Terauchi Y, Tamakoshi A, Atsumi T. Serum adiponectin and insulin secretion: A direct or inverse association? *J Diabetes Investig.* 9: 1106-1109, 2018
2. Cho KY, Nakamura A, Omori K, Takase T, Miya A, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Effect of switching from pioglitazone to the SGLT2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type-2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial. *Diabetes Obes Metab.* (in press).
3. Kameda H, Yamamoto M, Tone Y, Tone M, Melmed S. Proton sensitivity of corticotropin-releasing hormone receptor 1 signaling to proopiomelanocortin in male mice. *Endocrinology.* (in press).
4. Nomoto H, Miyoshi H, Nakamura A, Nagai S, Shimizu C, Atsumi T. Potential importance of histopathological analysis in thyroidal diseases with high serum IgG4 levels. *Intern Med.* 57: 453, 2018.
5. Nomoto H, Oita M. Thyrotoxicosis in Graves' disease with invasive laryngeal cancer. *Intern Med.* 57: 1495-1496, 2018.
6. Nomoto H, Miyoshi H, Sekizaki T, Atsumi T. Comment on "Elevation of Serum Carcinoembryonic Antigen Concentration Caused by Everolimus-Induced Lung Injury: A Case Report". *Ann Thorac Cardiovasc Surg.* 24: 165-166, 2018.
7. Yamamoto K, Miyoshi H, Cho KY, Nakamura A, Greenberg AS, Atsumi T. Overexpression of perilipin1 protects against atheroma progression in apolipoprotein E knockout mice. *Atherosclerosis.* 269: 192-196, 2018.
8. Yamamoto K, Miyoshi H, Cho KY, Nakamura A, Greenberg AS, Atsumi T. The data of change in macrophage gene expression which induced by perilipin 1 overexpression. *Data Brief.* 19: 179-182, 2018.
9. Miya A, Nakamura A, Miyoshi H, Cho KY, Nagai S, Kurihara Y, Aoki S, Taguri M, Terauchi Y, Atsumi T. Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: a randomized controlled trial. *J Diabetes Investig.* 9: 119-126, 2018.
10. Miya A, Nakamura A, Miyoshi H, Takano Y, Sunagoya K, Hayasaka K, Shimizu C, Terauchi Y, Atsumi T. Impact of glucose loading on variations in CD4+ and CD8+ T cells in Japanese participants with or without type 2 diabetes. *Front Endocrinol (Lausanne).* 9: 81, 2018.
11. Kitao N, Nakamura A, Miyoshi H, Nomoto H, Takahashi K, Omori K, Yamamoto K, Cho KY, Terauchi Y, Atsumi T. The role of glucokinase and insulin receptor substrate-

- 2 in the proliferation of pancreatic beta cells induced by short-term high-fat diet feeding in mice. *Metabolism*. 85: 48-58, 2018.
12. Takahashi K, Nakamura A, Miyoshi H, Nomoto H, Kitao N, Omori K, Yamamoto K, Cho KY, Terauchi Y, Atsumi T. Effect of the sodium–glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages. *Sci Rep*. 8: 6864, 2018.
  13. Takahashi K, Cho KY, Nakamura A, Miya A, Miyoshi A, Yamamoto C, Nomoto H, Niwa H, Takahashi K, Manda N, Kurihara Y, Aoki S, Ito Y, Atsumi T, Miyoshi H. Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicentre observational study in Japanese patients with type 2 diabetes. *J Diabetes Investig*, (in press).
  14. Takase T, Nakamura A, Yamamoto C, Atsumi T, Miyoshi H. Improvement in the proinsulin/C-peptide ratio during treatment with ipragliflozin in Japanese patients with type 2 diabetes mellitus. *Expert Opin Pharmacother*. 19: 631-632, 2018.
  15. Takase T, Nakamura A, Yamamoto C, Nomoto H, Miya A, Dan-noura M, Cho KY, Kurihara Y, Manda N, Aoki S, Atsumi T, Miyoshi H. Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: a randomized controlled trial. *J Diabetes Investig*, (in press).
  16. Omori K, Nomoto H, Nakamura A, Takase T, Cho KY, Ono K, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: a randomized controlled trial of repaglinide vs. sulfonylurea. *J Diabetes Investig*, (in press).
  17. Shibayama Y, Wada N, Baba S, Miyano Y, Obara S, Iwasaki R, Nakajima H, Sakai H, Kimura T, Usubuchi H, Terae S, Nakamura A, Atsumi T. Relationship between visceral fat and plasma aldosterone concentration in patients with primary aldosteronism. *J Endocr Soc*. 2: 1236-1245, 2018.
  18. Oita M, Miyoshi H, Ono K, Nakamura A, Cho KY, Nomoto H, Yamamoto K, Omori K, Manda N, Kurihara Y, Aoki S, Atsumi T. Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes -Randomized controlled study-. *Endocr J*. 65: 141-150, 2018.
  19. Yanagiya S, Cho KY, Nakamura A, Nomoto H, Kawamoto Y, Kawakubo K, Komatsu Y, Mitsuhashi T, Miyoshi H, Atsumi T. The effect of everolimus on refractory hypoglycemia in a patient with inoperable metastatic insulinoma evaluated by continuous glucose monitoring. *Intern Med*. 57: 2527-2531, 2018.
  20. Sekizaki T, Yamamoto C, Nomoto H. Two Cases of Transiently Elevated Serum CEA Levels in Severe Hypothyroidism without Goiter. *Intern Med*. 57: 2523-2526.
  21. Ujiie H, Muramatsu K, Mushiroda T, Ozeki T, Miyoshi H, Iwata H, Nakamura A, Nomoto H, Cho KY, Nishimura M, Ito T, Izumi K, Nishie W, Shimizu H. HLA-DQB1\*03:01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors. *J Invest Dermatol*. 138: 1201-1204, 2018.
  22. Babu GR, Nakamura A, Eržen DJ. Can short stature be a screening criteria for GDM? *Front Endocrinol (Lausanne)*, (in press).

23. Yamamoto M, Ben-Shlomo A, Kameda H, Fukuoka H, Deng N, Ding Y, Melmed S. Somatostatin receptor subtype 5 modifies hypothalamic-pituitary-adrenal axis stress function. *JCI Insight*. 3: e122932, 2018.低下症などの病態に關与していることが
24. Niwa H, Takahashi K, Dannoura M, Omori K, Miyoshi A, Inada T, Miyoshi H. The association of cardio-ankle vascular index and ankle brachial index with macroangiopathy in patients with type 2 diabetes mellitus. *J Atheroscler Thromb*, (in press).
25. Otagiri S, Ohnishi S, Miura A, Hayashi H, Kumagai I, Ito YM, Katsurada T, Nakamura S, Okamoto R, Yamahara K, Cho KY, Isoe T, Sato N, Sakamoto N. Evaluation of amnion-derived mesenchymal stem cells for treatment-resistant moderate Crohn's disease: study protocol for a phase I/II, dual-centre, open-label, uncontrolled, dose-response trial. *BMJ Open Gastroenterol*. 5: e000206, 2018.
26. Kawagishi N, Suda G, Nakamura A, Kimura M, Maehara O, Suzuki K, Nakamura A, Ohara M, Izumi T, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Miyoshi H, Sakamoto N. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. *PLoS One*, (in press).

[邦文論文・総説]

1. 三好秀明：「高齢者糖尿病患者についての最近の話題」『札幌内科医会会報』25(1)、13-15 (2018)
2. 三好秀明：「せんせい教えてください！「痩せられる薬があると聞いたのですが、私も使っていいものですか？」」『月刊糖尿病ライフ さかえ』58(10)、52-53 (2018)
3. 三好秀明：「SGLT2 阻害薬の有効性と安全性」『Diabetes Update』7(1)、4-14 (2018)
4. 三好秀明：「特集「糖尿病を防ぐ・治療する」 SGLT2 阻害薬と GLP-1 受容体作動薬」『クオリティ』53(5)、69-70 (2018)
5. 三好秀明：「糖尿病と NAFLD/NASH」『ベストナース』29(11)、31 (2018)
6. 中村昭伸：「北海道胆振東部地震における動物実験施設や実験動物への影響」『日本糖尿病・肥満動物学会 NEWS LETTER』22(2)、2 (2018)
7. 大場知穂、三好秀明：「耐糖能異常：グレーゾーンの人にはどこまでふみこめばよいのか」『Hospitalist』6(2)、310-314 (2018)
8. 宮愛香、三好秀明：「経口血糖降下薬にかかわる最近のエビデンス」『最新医学』73(1)、71-77 (2018)
9. 宮愛香、中村昭伸：「リポハイパートロフィー 糖尿病検査の考え方」『べんちのーと』28(4)、19 (2018)
10. 宮愛香、中村昭伸：「糖尿病と HbA1c 値 糖尿病検査の考え方」『べんちのーと』29(1)、19 (2018)
11. 宮愛香、中村昭伸：「糖尿病とグリコアルブミン 糖尿病検査の考え方」『べんちのーと』29(2)、19 (2018)

12. 宮愛香、中村昭伸：「糖尿病と簡易自己血糖測定 糖尿病検査の考え方」  
『べんちのーと』 29(3)、19 (2018)